Consensus Tempus AI, Inc. Buenos Aires S.E.

Stocks

TEM

AR0520934156

Biotechnology & Medical Research

End-of-day quote Buenos Aires S.E. 2026-09-28			5-day change	1st Jan Change
11,460.00 ^ARS	+0.09%		+10.72%	+49.80%

09-28	Tempus AI, Inc. Receives FDA Clearance For Tempus ECG-MR AI Product Designed To Identify Undiagnosed Mitral Regurgitation	CI
09-28	Tempus AI Receives FDA Clearance for ECG-MR Tool to Identify Moderate or Severe Mitral Regurgitation	MT

ab1220695f.iZzY3shg2XXUwlN_9-6srRN_cUAhASFkccEKD8eP_lQ.z82IgZhYijriiSNPzpzhn2EeSXVQLG0GKflbV4zHuyew9a2J8VOpOoOLMA~fbb02f18290d63787320d3a82f3ec2cd

Analysts' recommendations: Tempus AI, Inc.

09-21	Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target	MT
09-09	UBS Initiates Coverage on Tempus AI With Neutral Rating, $70 Price Target	MT
09-08	Rothschild & Co Redburn Initiates Tempus AI at Neutral With $67 Price Target	MT
09-02	Cantor Fitzgerald Initiates Tempus AI at Overweight With $80 Price Target	MT
09-01	Piper Sandler Upgrades Tempus AI to Overweight From Neutral, Adjusts PT to $76 From $56	MT
09-01	Analyst recommendations: Duolingo, Robinhood, Adobe, CrowdStrike, Salesforce…
07-20	Personalis Acquisition Price Warranted by Growth Prospects, Needham Says	MT
07-20	Tempus AI to Buy Cancer Test Maker Personalis; Needham Says Deal Premium Well Above Peers	MT
07-20	Top Midday Decliners	MT
04-13	TD Cowen Upgrades Tempus AI to Buy From Hold, Adjusts Price Target to $65 From $70	MT
04-13	Jefferies Initiates Tempus AI at Underperform With $35 Price Target	MT
02-25	Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead…
02-19	Mizuho Securities Initiates Coverage on Tempus AI With Outperform Rating, $100 Price Target	MT
02-17	Baird Initiates Tempus AI at Outperform With $59 Price Target	MT
12-02	Morgan Stanley Raises Price Target on Tempus AI to $85 From $80, Keeps Overweight Rating	MT
11-11	Analyst recommendations: Coreweave, Duolingo, Lyft, Qualcomm, Tempus…
25-10-22	Analyst recommendations: 3M Company, Gartner, Halliburton, GM, Warner Bros Discovery…
25-10-21	Tempus AI Shares Lower After TD Cowen Downgrade	MT
25-10-21	TD Cowen Downgrades Tempus AI to Hold From Buy, Adjusts Price Target to $88 From $72	MT
25-10-20	Canaccord Genuity Initiates Coverage on Tempus AI With Buy Rating, $110 Price Target	MT
25-09-02	HC Wainwright Initiates Tempus AI at Buy With $90 Price Target	MT
25-08-05	Healthcare firm Personalis' Q2 revenue misses estimates	RE
25-04-21	BTIG Initiates Tempus AI at Buy With $60 Price Target	MT
25-02-26	Wolfe Research Downgrades Tempus AI to Peer Perform From Outperform	MT
25-02-25	Tempus AI Shares Fall After Downgrade from JPMorgan	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	LONZA GROUP AG					+20.9%
	IQVIA HOLDINGS INC.					+3.4%
	REVOLUTION MEDICINES, INC.					+23.88%
	BEONE MEDICINES AG					+19.94%
	CELLTRION, INC.					+50.95%
	MEDPACE HOLDINGS, INC.					-5.99%
	TEMPUS AI, INC.					-19.36%
	EUROFINS SCIENTIFIC SE					-6.61%
	ASCENDIS PHARMA A/S					+37.6%
	Average					+13.86%
	Weighted average by Cap.					+17.03%